Roelof Botha’s Post

Applications for Sequoia Capital Arc are now open. We launched this 7-week immersion to share lessons from 50 yrs of company-building experience. We often ask founders: What’s the scale of your ambition? If you have a transformational idea, we’d love to hear from you. Learn more here: 🔗 seq.vc/arc

It was a pleasure getting to spend time with founders across Europe last week. Team Sequoia Capital is incredibly enthusiastic about the momentum in the startup ecosystems here. It was lovely chatting with Emily Chang at Bloomberg about building in a challenging market, our long-term outlook with portfolio companies, investing in AI, and more. Watch the full interview here: https://lnkd.in/gPrXAYgY

Earlier this year, the US Surgeon General declared loneliness as a critical public health crisis affecting both individual and societal health. We Sequoia Capital are proud to partner with Renate Nyborg and the Meeno team as they help address the loneliness epidemic. Meeno is a non-judgmental AI mentor that empowers people to master the skill of social connection. Learn more here: https://lnkd.in/g-Bud2wz 

Crucible Moments: The Pivotal Decisions That Define Us

Today Sequoia launched Atlas–an interactive guide to Europe's tech talent. I have long believed that you can be from anywhere and achieve whatever you set out to–you don't have to move to the biggest city on the continent to find your people. Atlas is designed to help you find those people. We are incredibly excited about the future of Europe’s tech and startup communities and look forward to partnering with outlier founders from across the continent. Learn more here: https://lnkd.in/gqzdCKqx

It was great talking to Tim Ferriss (https://lnkd.in/gbRDxYsk) about everything from growing up in South Africa, the concept of the founder-problem fit, and our philosophy and approach to building legendary companies here at Sequoia. Listen here: https://lnkd.in/g-ndF8Ty

Today we’re proud to introduce the Sequoia Fund, a permanent fund without the limitations of liquidity restrictions or the traditional 10-year VC fund cycle. It’s a bold change during a crucible moment in our journey, and we’re excited to support the outlier founders of today, tomorrow, and beyond. https://lnkd.in/gjvmdaAn

I'm excited about the potential to harness precision genetic engineering to treat a variety of illnesses. Genedit's technology is a key enabler to deliver these therapies, which is why we led the Seed financing in 2016 as its First Believer.

What a fun conversation with Harry Stebbings!